Healthy participants
Conditions
Interventions
Group 1: Healthy particpants, pharmacological challenge (single dose) with Madopar®250 mg vs. placebo (lactose). Followed by eye movement tasks. Modelling of data with mathematical models.
Group 2: He
Sponsors
Translational Neuromodeling Unit, Institut für Biomedizinische Technik, Universität Zürich und ETH Zürich
Eligibility
Sex/Gender
Male
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: • Age: =18 and =40 years • Male sex • European ancestry • Written informed consent • Consent to adhere to the study protocol • Ability to adhere to the study protocol
Exclusion criteria
Exclusion criteria: General: • Serious past or present brain disease, brain injury or brain surgery • Any neurological or psychiatric disorders (past or present) • Current psychoactive medication • Daily nicotin use • Daily alcohol use > 2 units per day on average (1 unit = 3 dl beer = 1 dl wine) • Current use of recreational drugs • History of drug abuse • Any current severe medical condition Additional exclusion criteria for the pharmacological study branches: • Tachy- or bradycardia (normal range 55-100 bpm), cardiac arrhythmia and/or QTc-time >430 ms • History of severe kidney or liver disorder • Prostate or bladder disorder • Glaucoma • Asthma or other obstructive respiratory disease • Current medication known to interact with levodopa, benserazide, or galantamine • Allergy to lactose, levodopa, benserazide, or galantamine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Goal of the study: Understanding how neuromodulators modulate the control of saccadic eye movements. Modelparameters of eye movement models will be compared statistically between drug and placebo conditions. | — |
Countries
Switzerland
Contacts
Public ContactJakob Heinzle
Translational Neuromodeling Unit, Institut für Biomedizinische Technik, Universität Zürich und ETH Zurich
Outcome results
None listed